Evidence map›Paper›PMID 39997827›Full record

ReviewNanomaterials (Basel, Switzerland)2025

Magnetic-Plasmonic Core-Shell Nanoparticles: Properties, Synthesis and Applications for Cancer Detection and Treatment.

Alberto Luis Rodriguez-Nieves, Suprava Shah, Mitchell L Taylor, Madhusudhan Alle, Xiaohua Huang

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alberto Luis Rodriguez-NievesDepartment of Chemistry, The University of Memphis, Memphis, TN 38152, USA.ORCID 0000-0001-9927-4404
Suprava ShahDepartment of Chemistry, The University of Memphis, Memphis, TN 38152, USA.ORCID 0009-0007-9992-7680
Mitchell L TaylorDepartment of Chemistry, The University of Memphis, Memphis, TN 38152, USA.ORCID 0000-0002-6997-7800
Madhusudhan AlleDepartment of Chemistry, The University of Memphis, Memphis, TN 38152, USA.ORCID 0000-0002-3095-5479
Xiaohua HuangDepartment of Chemistry, The University of Memphis, Memphis, TN 38152, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticles have been widely used in cancer diagnostics and treatment research due to their unique properties. Magnetic nanoparticles are popular in imaging techniques due to their ability to alter the magnetization field around them. Plasmonic nanoparticles are mainly applied in cancer treatments like photothermal therapy due to their ability to convert light into heat. While these nanoparticles are popular among their respective fields, magnetic-plasmonic core-shell nanoparticles (MPNPs) have gained popularity in recent years due to the combined magnetic and optical properties from the core and shell. MPNPs have stood out in cancer theranostics as a multimodal platform capable of serving as a contrast agent for imaging, a guidable drug carrier, and causing cellular ablation through photothermal energy conversion. In this review, we summarize the different properties of MPNPs and the most common synthesis approaches. We particularly discuss applications of MPNPs in cancer diagnosis and treatment based on different mechanisms using the magnetic and optical properties of the particles. Lastly, we look into current challenges they face for clinical applications and future perspectives using MPNPs for cancer detection and therapy.

Indexed as

cancer detectioncancer treatmentcore–shellmagnetic–plasmonic nanoparticlesmagnetic propertyoptical property

Identifiers

PMID39997827
PMCPMC11858323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.